Reduction of dopamine-related transcription factors Nurr1 and NGFI-B in the prefrontal cortex in schizophrenia and bipolar disorders

Schizophrenia Research

Volumn 84, Issue 1, 2006, Pages 36-56

  Xing, Guoqiang ^a,b   Zhang, Lei ^a   Russell, Shani ^a,b   Post, Robert ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Affective illness; Cell density; Dopaminergic; GFAP; Maturation; Prefrontal cortex; Schizophrenia; Transcription factor

Indexed keywords

DOPAMINE; EARLY GROWTH RESPONSE FACTOR B; MESSENGER RNA; NUCLEAR RECEPTOR RELATED FACTOR 1; NUCLEIC ACID BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIPOLAR DISORDER; CELL DENSITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR DEPRESSION; NEUROPATHOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCHIZOPHRENIA; WESTERN BLOTTING;

ADULT; BIPOLAR DISORDER; BLOTTING, WESTERN; DNA PRIMERS; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOBLOTTING; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREFRONTAL CORTEX; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RNA, MESSENGER; SCHIZOPHRENIA; TRANSCRIPTION FACTORS;

EID: 33646524277     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.11.006     Document Type: Article

References (68)

1. Akbarian S., Bunney Jr. W.E., Potkin S.G., et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch. Gen. Psychiatry 50 (1993) 169-177
2. Akil M., Pierri J.N., Whitehead R.E., et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am. J. Psychiatry 156 (1999) 1580-1589
3. Arimatsu Y., Ishida M., Kaneko T., Ichinose S., and Omori A. Organization and development of corticocortical associative neurons expressing the orphan nuclear receptor Nurr1. J. Comp. Neurol. 466 (2003) 180-196
4. Bayer S.A. Neurogenetic patterns in the medial limbic cortex of the rat related to anatomical connections with the thalamus and striatum. Exp. Neurol. 107 (1990) 132-142
5. Beaudry G., Langlois M.C., Weppe I., Rouillard C., and Levesque D. Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain. J. Neurochem. 75 (2000) 1694-1702
6. Bloom F.E. Advancing a neurodevelopmental origin for schizophrenia. Arch. Gen. Psychiatry 50 (1993) 224-227
7. Buervenich S., Carmine A., Arvidsson M., et al. NURR1 mutations in cases of schizophrenia and manic-depressive disorder. Am. J. Med. Genet. 96 (2000) 808-813
8. Byne W., and Davis K.L. The role of prefrontal cortex in the dopaminergic dysregulation of schizophrenia. Biol. Psychiatry 45 (1999) 657-659
9. Castro D.S., Hermanson E., Joseph B., et al. Induction of cell cycle arrest and morphological differentiation by Nurr1 and retinoids in dopamine MN9D cells. J. Biol. Chem. 276 (2001) 43277-43284
10. Cheramy A., Romo R., and Glowinski J. The relative roles of neuronal activity and direct presynaptic mechanisms in controlling the release of dopamine from the cat caudate nucleus. Ann. N. Y. Acad. Sci. 473 (1986) 80-91
11. Chung S., Sonntag K.C., Andersson T., et al. Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. Eur. J. Neurosci. 16 (2002) 1829-1838
12. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148 (1991) 1474-1486
13. Eells J.B. The control of dopamine neuron development, function and survival: insights from transgenic mice and the relevance to human disease. Curr. Med. Chem. 10 (2003) 857-870
14. Eells J.B., Lipska B.K., Yeung S.K., Misler J.A., and Nikodem V.M. Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity. Behav. Brain Res. 136 (2002) 267-275
15. Ethier I., Beaudry G., St-Hilaire M., Milbrandt J., Rouillard C., and Levesque D. The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression. Neuropsychopharmacology 29 (2004) 335-346
16. Falkai P., and Bogerts B. Cell loss in the hippocampus of schizophrenics. Eur. Arch. Psychiatr. Neurol. Sci. 236 (1986) 154-161
17. Farde L., Wiesel F.A., Halldin C., and Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry 45 (1988) 71-76
18. Glantz L.A., and Lewis D.A. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch. Gen. Psychiatry 54 (1997) 943-952
19. Haas S.J., and Wree A. Dopaminergic differentiation of the Nurr1-expressing immortalized mesencephalic cell line CSM14.1 in vitro. J. Anat. 201 (2002) 61-69
20. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122 4 (1999) 593-624
21. Iwawaki T., Kohno K., and Kobayashi K. Identification of a potential nurr1 response element that activates the tyrosine hydroxylase gene promoter in cultured cells. Biochem. Biophys. Res. Commun. 274 (2000) 590-595
22. Jin G.Z., Zhu Z.T., and Fu Y. (-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions. Trends Pharmacol. Sci. 23 (2002) 4-7
23. Johnston-Wilson N.L., Sims C.D., Hofmann J.P., et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol. Psychiatry 5 (2000) 142-149
24. Kapur S., Zipursky R., Jones C., Remington G., and Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157 (2000) 514-520
25. Kim J.Y., Koh H.C., Lee J.Y., et al. Dopaminergic neuronal differentiation from rat embryonic neural precursors by Nurr1 overexpression. J. Neurochem. 85 (2003) 1443-1454
26. Kim K.S., Kim C.H., Hwang D.Y., et al. Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner. J. Neurochem. 85 (2003) 622-634
27. Knable M.B., Torrey E.F., Webster M.J., and Bartko J.J. Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res. Bull. 55 (2001) 651-659
28. Law S.W., Conneely O.M., DeMayo F.J., and O'Malley B.W. Identification of a new brain-specific transcription factor, NURR1. Mol. Endocrinol. 6 (1992) 2129-2135
29. Le Moal M., Stinus L., and Simon H. Increased sensitivity to (+)amphetamine self-administered by rats following meso-cortico-limbic dopamine neurone destruction. Nature 280 (1979) 156-158
30. Le W., Conneely O.M., He Y., Jankovic J., and Appel S.H. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J. Neurochem. 73 (1999) 2218-2221
31. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., and Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28 (2000) 53-67
32. Murphy E.P., and Conneely O.M. Neuroendocrine regulation of the hypothalamic pituitary adrenal axis by the nurr1/nur77 subfamily of nuclear receptors. Mol. Endocrinol. 11 (1997) 39-47
33. Murphy E.P., McEvoy A., Conneely O.M., Bresnihan B., and FitzGerald O. Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotropin-releasing hormone expression and actions in human inflammatory arthritis. Arthritis Rheum. 44 (2001) 782-793
34. Ojeda V., Fuentealba J.A., Galleguillos D., and Andres M.E. Rapid increase of Nurr1 expression in the substantia nigra after 6-hydroxydopamine lesion in the striatum of the rat. J. Neurosci. Res. 73 (2003) 686-697
35. Okabe T., Takayanagi R., Adachi M., Imasaki K., and Nawata H. Nur77, a member of the steroid receptor superfamily, antagonizes negative feedback of ACTH synthesis and secretion by glucocorticoid in pituitary corticotrope cells. J. Endocrinol. 156 (1998) 169-175
36. Okubo Y., Suhara T., Suzuki K., et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385 (1997) 634-636
37. Perrone-Bizzozero N.I., Sower A.C., Bird E.D., Benowitz L.I., Ivins K.J., and Neve R.L. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14182-14187
38. Picon A., Bertagna X., and de Keyzer Y. Analysis of proopiomelanocortin gene transcription mechanisms in bronchial tumour cells. Mol. Cell. Endocrinol. 147 (1999) 93-102
39. Pycock C.J., Kerwin R.W., and Carter C.J. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 286 (1980) 74-76
40. Rajkowska G., and Goldman-Rakic P.S. Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. Cereb. Cortex 5 (1995) 307-322
41. Rajkowska G., Selemon L.D., and Goldman-Rakic P.S. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch. Gen. Psychiatry 55 (1998) 215-224
42. Rajkowska G., Miguel-Hidalgo J.J., Makkos Z., Meltzer H., Overholser J., and Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr. Res. 57 (2002) 127-138
43. Sacchetti P., Mitchell T.R., Granneman J.G., and Bannon M.J. Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism. J. Neurochem. 76 (2001) 1565-1572
44. Sakurada K., Ohshima-Sakurada M., Palmer T.D., and Gage F.H. Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development 126 (1999) 4017-4026
45. Saucedo-Cardenas O., and Conneely O.M. Comparative distribution of NURR1 and NUR77 nuclear receptors in the mouse central nervous system. J. Mol. Neurosci. 7 (1996) 51-63
46. Saucedo-Cardenas O., Quintana-Hau J.D., Le W.D., et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4013-4018
47. Selemon L.D., Rajkowska G., and Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry 52 (1995) 805-818 discussion 819-20
48. Selemon L.D., Rajkowska G., and Goldman-Rakic P.S. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J. Comp. Neurol. 392 (1998) 402-412
49. Selemon L.D., Mrzljak J., Kleinman J.E., Herman M.M., and Goldman-Rakic P.S. Regional specificity in the neuropathologic substrates of schizophrenia: a morphometric analysis of Broca's area 44 and area 9. Arch. Gen. Psychiatry 60 (2003) 69-77
50. Shoemaker J.M., Saint Marie R.L., Bongiovanni M.J., Neary A.C., and Tochen L.S. Prefrontal D1 and ventral hippocampal N-methyl-d-aspartate regulation of startle gating in rats. Neuroscience 135 (2005) 385-394
51. Smits S.M., Ponnio T., Conneely O.M., Burbach J.P., and Smidt M.P. Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons. Eur. J. Neurosci. 18 (2003) 1731-1738
52. Torrey E.F., Webster M., Knable M., Johnston N., and Yolken R.H. The Stanley foundation brain collection and neuropathology consortium. Schizophr. Res. 44 (2000) 151-155
53. Tseng K.Y., Roubert C., Do L., et al. Selective increase of Nurr1 mRNA expression in mesencephalic dopaminergic neurons of D2 dopamine receptor-deficient mice. Brain Res. Mol. Brain Res. 80 (2000) 1-6
54. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., and Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 67 (2004) 269-275
55. Wagner J., Akerud P., Castro D.S., et al. Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. Nat. Biotechnol. 17 (1999) 653-659
56. Wallen A., Zetterstrom R.H., Solomin L., Arvidsson M., Olson L., and Perlmann T. Fate of mesencephalic AHD2-expressing dopamine progenitor cells in NURR1 mutant mice. Exp. Cell Res. 253 (1999) 737-746
57. Webster M.J., Knable M.B., Johnston-Wilson N., Nagata K., Inagaki M., and Yolken R.H. Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar disorder, and depression. Brain Behav. Immun. 15 (2001) 388-400
58. Webster M.J., O'Grady J., Kleinman J.E., and Weickert C.S. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 133 (2005) 453-461
59. Werme M., Thoren P., Olson L., and Brene S. Addiction-prone Lewis but not Fischer rats develop compulsive running that coincides with downregulation of nerve growth factor inducible-B and neuron-derived orphan receptor 1. J. Neurosci. 19 (1999) 6169-6174
60. Werme M., Ringholm A., Olson L., and Brene S. Differential patterns of induction of NGFI-B, Nor1 and c-fos mRNAs in striatal subregions by haloperidol and clozapine. Brain Res. 863 (2000) 112-119
61. Xing G., Zhang L., Heynen T., et al. Rat nurr1 is prominently expressed in perirhinal cortex, and differentially induced in the hippocampal dentate gyrus by electroconvulsive vs. kindled seizures. Brain Res. Mol. Brain Res. 47 (1997) 251-261
62. Xing G.Q., Zhang L.-X., Yang S., and Post R.M. Increased expression of inducible nitric oxide synthase and decreased glia fibrillary acidic protein (GFAP) in the postmortem prefrontal cortex of the unipolar depressive and schizophrenic individuals. The American College of Neuropsychopharmacology 38th Annual Meeting. Acapulco, Mexico (1999)
63. Xing G., Russell S., Hough C., et al. Decreased prefrontal CaMKII alpha mRNA in bipolar illness. Neuroreport 13 (2002) 501-505
64. Zetterstrom R.H., Solomin L., Mitsiadis T., Olson L., and Perlmann T. Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. Mol. Endocrinol. 10 (1996) 1656-1666
65. Zetterstrom R.H., Williams R., Perlmann T., and Olson L. Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Brain Res. Mol. Brain Res. 41 (1996) 111-120
66. Zetterstrom R.H., Solomin L., Jansson L., Hoffer B.J., Olson L., and Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 276 (1997) 248-250
67. Zhu Z.T., Fu Y., Hu G.Y., and Jin G.Z. Modulation of medical prefrontal cortical D1 receptors on the excitatory firing activity of nucleus accumbens neurons elicited by (-)-Stepholidine. Life Sci. 67 (2000) 1265-1274
68. Zhu Z.T., Wu W.R., Fu Y., and Jin G.Z. I-stepholidine facilitates inhibition of mPFC DA receptors on subcortical NAc DA release. Acta Pharmacol. Sin. 21 (2000) 663-667